EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring the potential effect of pentoxifylline in mitigating vascular calcification in chronic kidney disease patients

Dina M. Gaber, Ghada M. El-Kannishy, Ahmed Y. Elmowafy, Huda F. Refaie, Ahmed M. Abdel-Rahman

Journal of The Egyptian Society of Nephrology and Transplantation · 2026-04 · 26 (2) · 109-118

DOI: 10.4103/jesnt.jesnt_4_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of The Egyptian Society of Nephrology and Transplantation, online erschienen am 02.04.2026. Verfasst von Dina M. Gaber und 4 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronary artery calcification (CAC) is highly prevalent in patients with chronic kidney disease (CKD) and is strongly associated with adverse cardiovascular outcomes. Pentoxifylline (PTX), a methylxanthine derivative with anti-inflammatory and hemorheologic properties, may have a potential role in attenuating vascular calcification and slowing CKD progression. Patients and methods This prospective, open-label, randomized controlled trial included 80 CKD patients were randomized to receive either PTX 400 mg twice daily plus conventional therapy ( n =40) or conventional therapy alone ( n =40) for 6 months. Baseline and follow-up assessments included clinical evaluation, laboratory investigations, and coronary artery calcium scoring using multislice computed tomography with the Agatston method. The primary outcome was progression of CAC, while secondary outcomes included CKD progression and changes in renal and biochemical parameters.

Results

Baseline demographic, clinical, and laboratory characteristics were comparable. After 6 months, estimated glomerular filtration rate declined significantly in the control group but remained stable in the PTX group. CKD progression was less frequent in PTX group (12.5 vs. 32.5%, P =0.032). The Agatston score increased significantly in the control group but decreased in the PTX group, with a significantly lower score observed in the intervention arm ( P =0.036). Regression of coronary calcification occurred more frequently with PTX (27.5 vs. 5%, P =0.023). Multivariate analysis identified group allocation as the sole independent predictor of CAC progression.

Conclusion

PTX therapy significantly attenuated CAC progression and was associated with reduced CKD progression in patients with moderate to advanced CKD.

Zitieren

APA

Gaber, D. M., El-Kannishy, G. M., Elmowafy, A. Y., Refaie, H. F., & Abdel-Rahman, A. M. (2026). Exploring the potential effect of pentoxifylline in mitigating vascular calcification in chronic kidney disease patients. Journal of The Egyptian Society of Nephrology and Transplantation, 26(2), 109-118. https://doi.org/10.4103/jesnt.jesnt_4_26

Vancouver

Gaber DM, El-Kannishy GM, Elmowafy AY, Refaie HF, Abdel-Rahman AM. Exploring the potential effect of pentoxifylline in mitigating vascular calcification in chronic kidney disease patients. Journal of The Egyptian Society of Nephrology and Transplantation. 2026;26(2):109-118. doi:10.4103/jesnt.jesnt_4_26

BibTeX
@article{Gaber2026,
  author = {Gaber, Dina M. and El-Kannishy, Ghada M. and Elmowafy, Ahmed Y. and Refaie, Huda F. and Abdel-Rahman, Ahmed M.},
  title = {Exploring the potential effect of pentoxifylline in mitigating vascular calcification in chronic kidney disease patients},
  journal = {Journal of The Egyptian Society of Nephrology and Transplantation},
  year = {2026},
  volume = {26},
  number = {2},
  pages = {109--118},
  doi = {10.4103/jesnt.jesnt_4_26}
}
Kostenlos starten →